Our goal is to commercialize (from clinical trials and FDA approvals, to manufacturing and sales) CAR-T cell therapeutics that treat metastatic cancer arising from the gastrointestinal tract.
To achieve this objective, we have obtained a license for all Guanylyl Cyclase C (GCC) CAR-T-related patents and know-how from Targeted Diagnostics & Therapeutics, Inc. (TDT).
Our CAR-T therapeutics utilize GCC, which is a tumor marker for nearly all metastatic colorectal cancers, and many tumors arising in the stomach, pancreas, and esophagus, developed by Dr. Scott A. Waldman’s team at Thomas Jefferson University.
About GCC CAR-T therapeutics:
- Ability to target solid tumors based on the discovery that GCC is expressed in primary/metastatic tumor cells arising from the gastrointestinal tract
- Technology developed using third-generation CAR-T cell therapeutics
